REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT
Introduction: Chronic Myeloid Leukemia (CML) typically progresses through chronic, accelerated, and blast phases, with most patients responding well to Tyrosine Kinase Inhibitors (TKIs) in the chronic phase. However, patients with Accelerated-Phase (AP) CML who develop high blast counts and TKI resi...
Saved in:
Main Authors: | Büşra Akdoğan, Ali Turunç, Birol Güvenç |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-07-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137925001804 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01) -
The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01) -
Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01) -
The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia
by: S. I. Kutsev, et al.
Published: (2010-06-01) -
Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)